BCM
Boone Capital Management Portfolio holdings
AUM
$233M
This Quarter Return
-4.97%
1 Year Return
+15.17%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$383M
AUM Growth
+$383M
(-22%)
Cap. Flow
-$75.3M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
75.36%
Holding
24
New
3
Increased
6
Reduced
9
Closed
5
Top Buys
| 1 |
IQVIA
IQV
|
$20M |
| 2 |
Danaher
DHR
|
$10.1M |
| 3 |
Charles River Laboratories
CRL
|
$9.98M |
| 4 |
Certara
CERT
|
$9.96M |
| 5 |
Globus Medical
GMED
|
$7.36M |
Top Sells
| 1 |
Enovis
ENOV
|
$35.1M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
$25M |
| 3 |
Mesa Laboratories
MLAB
|
$14.6M |
| 4 |
Viatris
VTRS
|
$13.5M |
| 5 |
BERY
Berry Global Group, Inc.
BERY
|
$11.2M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 12.4% |
| 3 | Materials | 3.99% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Unum
UNM
$11.9B
| $47.6M | 12.4% | 930,545 -94,482 | -9% | -$4.83M |
|
|
2
Globus Medical
GMED
$8.27B
| $43.6M | 11.38% | 637,315 +107,490 | +20% | +$7.36M |
|
3
Cigna
CI
$80.3B
| $43.6M | 11.37% | 131,926 | – | – |
|
4
Molina Healthcare
MOH
$9.8B
| $29.5M | 7.68% | 99,094 +13,378 | +16% | +$3.98M |
|
|
5
Danaher
DHR
$147B
| $26.6M | 6.93% | 106,360 +40,549 | +62% | +$10.1M |
|
6
Baxter International
BAX
$12.7B
| $24.1M | 6.29% | 721,278 +23,321 | +3% | +$780K |
|
|
7
IQVIA
IQV
$32.4B
| $20M | 5.22% | +94,734 | New | +$20M |
|
8
Amphastar Pharmaceuticals
AMPH
$1.42B
| $19.8M | 5.17% | 495,089 -111,599 | -18% | -$4.46M |
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $17.9M | 4.67% | 523,679 +71,781 | +16% | +$2.45M |
|
10
Pennant Group
PNTG
$830M
| $16.2M | 4.23% | 699,966 +135,774 | +24% | +$3.15M |
|
|
BERY
11
DELISTED
Berry Global Group, Inc.
BERY
| $15.3M | 3.99% | 259,710 -190,391 | -42% | -$11.2M |
|
12
IDEAYA Biosciences
IDYA
$2.15B
| $14.8M | 3.86% | 422,049 -109,918 | -21% | -$3.86M |
|
13
Orthofix Medical
OFIX
$592M
| $10.3M | 2.68% | 775,368 -199,134 | -20% | -$2.64M |
|
|
14
Charles River Laboratories
CRL
$8.04B
| $9.98M | 2.6% | +48,288 | New | +$9.98M |
|
|
15
Certara
CERT
$1.74B
| $9.96M | 2.6% | +718,983 | New | +$9.96M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $9.77M | 2.55% | 250,460 -40,943 | -14% | -$1.6M |
|
17
Viking Therapeutics
VKTX
$3.04B
| $9.26M | 2.42% | 174,766 -135,696 | -44% | -$7.19M |
|
18
Healthcare Services Group
HCSG
$1.13B
| $9.24M | 2.41% | 873,018 -53,437 | -6% | -$565K |
|
19
Tarsus Pharmaceuticals
TARS
$2.47B
| $5.87M | 1.53% | 216,047 -393,057 | -65% | -$10.7M |
|
|
20
Bio-Rad Laboratories Class A
BIO
$8.06B
| – | – | -72,344 | Closed | -$25M |
|
|
21
Enovis
ENOV
$1.77B
| – | – | -562,739 | Closed | -$35.1M |
|
|
22
Mesa Laboratories
MLAB
$373M
| – | – | -133,394 | Closed | -$14.6M |
|
23
Quanterix
QTRX
$211M
| – | – | -330,151 | Closed | -$7.78M |
|
|
24
Viatris
VTRS
$12.3B
| – | – | -1,133,591 | Closed | -$13.5M |
|